- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Human epidermal growth factor receptor 2 (HER2)-low breast cancer
- Meeting Date: March 2024
- Public Summary Document (PSD) March 2024 PBAC Meeting - (PDF 762KB)
- Public Summary Document (PSD) March 2024 PBAC Meeting - (Word 236KB)
Trastuzumab deruxtecan – March 2024
Trastuzumab Deruxtecan: Powder for I.V. infusion 100 mg; Enhertu®
Last updated
30 May 2025